# SEQUOIA (NCT03336333)

> A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

No report yet. It can be ordered.

- Drugs tested: zanubrutinib; zanubrutinib plus venetoclax
- Indication: previously untreated CLL/SLL

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03336333
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: BeiGene
- Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
- Interventions: Zanubrutinib; Bendamustine; Rituximab; Venetoclax
- Enrollment: 590
- Primary outcome: Cohort 1: Progression-free Survival (PFS) as Determined by Independent Central Review (ICR)

## Indexed commentary on SEQUOIA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 125
- Podcasts: 88
- X threads: 32
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=sequoia-nct03336333

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03336333", "email": "<work email>"}; the inbox owner confirms by the emailed link.